Search results
Amgen 'encouraged' by weight-loss drug interim data, shares jump By Reuters
Investing.com· 7 days agoInvestors are focused on Amgen's pipeline of experimental weight-loss drugs, and the company said it...
Amgen Inc (AMGN) Q1 2024 Earnings Call Transcript Highlights: Strong Growth and Strategic Advances
GuruFocus.com via Yahoo Finance· 6 days agoNegative Points Despite overall strong performance, Enbrel sales decreased by 2% year-over-year in the first quarter, driven by volume decline. The company's non-GAAP operating ...
Amgen Shares Jump After Teasing 'Encouraging' Weight Loss Data
US News & World Report· 6 days agoInvestors late Thursday shrugged off a slight drop in the company's first-quarter adjusted profit and slightly-lower-than expected sales of drugs including arthritis treatment Enbrel ...
Amgen (NASDAQ:AMGN) Rating Increased to Outperform at William Blair
ETF DAILY NEWS· 4 days agoAmgen (NASDAQ:AMGN – Get Free Report) was upgraded by William Blair from a “market perform” rating to an “outperform” rating in a research report issued to clients and investors on Friday, MarketBeat ...
Q2 2024 EPS Estimates for Amgen Inc. Reduced by Leerink Partnrs (NASDAQ:AMGN)
ETF DAILY NEWS· 2 days agoAmgen Inc. (NASDAQ:AMGN – Free Report) – Stock analysts at Leerink Partnrs reduced their Q2 2024 earnings estimates for Amgen in a research report issued on Friday, May 3rd. Leerink Partnrs ...
Amgen's Options: A Look at What the Big Money is Thinking - Amgen (NASDAQ:AMGN)
Benzinga· 7 days agoFlagship drugs include red blood cell boosters Epogen and Aranesp, immune system boosters Neupogen and Neulasta, and Enbrel and Otezla for inflammatory diseases. Amgen introduced ...
Amgen (NASDAQ:AMGN) Price Target Cut to $328.00
ETF DAILY NEWS· 4 days agoAmgen (NASDAQ:AMGN – Get Free Report) had its price target reduced by Royal Bank of Canada from $332.00 to $328.00 in a note issued to investors on Friday, Benzinga reports. The brokerage presently ...
Amgen (NASDAQ:AMGN) Shares Down 2.7% on Insider Selling
ETF DAILY NEWS· 2 days agoAmgen Inc. (NASDAQ:AMGN – Get Free Report) shares were down 2.7% on Monday after an insider sold shares in the company. The company traded as low as $301.09 and last traded at $302.91. Specifically ...
Biogen (NASDAQ:BIIB) Given New $342.00 Price Target at HSBC
ETF DAILY NEWS· 2 days agoBiogen (NASDAQ:BIIB – Free Report) had its price objective boosted by HSBC from $339.00 to $342.00 in a research note published on Friday morning, Benzinga reports. BTIG Research restated a ...